Optimizing Pulmonology Denial Appeal Automation

Klivira streamlines pulmonology denial appeal automation, transforming complex, high-volume denials for asthma biologics and home oxygen into efficient, automated workflows.

Revenue cycle directors and prior authorization coordinators in pulmonology face significant challenges with denied claims, particularly for high-cost biologics and durable medical equipment. Manual appeal processes are labor-intensive, prone to errors, and frequently lead to lost revenue. Klivira's platform provides a targeted solution to automate these critical workflows, ensuring timely and evidence-based appeal submissions.

The Challenge of Pulmonology Denials

Denials in pulmonology often stem from specific clinical criteria not being explicitly met or documented in the initial prior authorization submission. For high-cost asthma biologics like Dupixent, Nucala, Fasenra, and Tezspire, common denial reasons include unmet step-therapy requirements or eosinophil-count thresholds. Similarly, home oxygen and BiPAP often face medical necessity denials. Manually addressing these denials requires deep clinical understanding and meticulous documentation retrieval, consuming valuable staff time and delaying patient access to care.

High-Volume Pulmonology PA Triggers Leading to Denials

Asthma biologics: omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), tezepelumab (Tezspire)
Home oxygen and BiPAP/CPAP equipment
IPF (idiopathic pulmonary fibrosis) antifibrotics: pirfenidone (Esbriet), nintedanib (Ofev)
Pulmonary function testing (PFTs) and advanced diagnostic imaging
Pulmonary rehabilitation programs

Klivira's Automated Appeal Workflow for Pulmonology

Klivira's platform leverages a payer-policy library and clinical guideline awareness (e.g., GINA, GOLD, ATS) to automate the denial appeal process for pulmonology. Our system classifies denials using normalized CARC/RARC taxonomy and selects the appropriate appeal pathway based on payer-specific rules. For clinical-necessity appeals, Klivira drafts clinician-reviewable letters, incorporating relevant literature and patient-specific data, significantly reducing the manual burden on your team.

Key Automation Steps in Pulmonology Denial Appeals

**Denial Classification**: Automated routing of pulmonology denials based on X12 CARC/RARC codes, identifying specific reasons like 'step therapy not met' or 'eosinophil count threshold not reached'.
**Documentation Re-discovery**: FHIR-based extraction of additional clinical evidence from the EMR, including updated eosinophil counts, spirometry results, exacerbation history, or prior controller therapy details.
**Appeal Letter Generation**: Automated assembly of appeal letters using payer-specific templates, tailored to address pulmonology denial reasons and incorporating relevant clinical guidelines.
**Payer Channel Submission**: Automated submission of appeal packets via payer portals, fax, or PAS-conformant resubmission, ensuring adherence to payer-specific requirements.
**Status Tracking & Escalation**: Proactive monitoring of appeal status with timely-filing window enforcement and automated escalation rules to prevent lost-to-follow-up appeals.

Seamless EMR Integration for Pulmonology Documentation

Klivira integrates directly with your EMR via SMART on FHIR, enabling real-time access to critical pulmonology-specific clinical documentation. This includes lab results (e.g., eosinophil counts), detailed physician notes on exacerbation history, spirometry data, and records of prior step-therapy failures. This automated evidence extraction ensures that appeal packets are comprehensive and clinically robust, directly addressing the specific requirements outlined in payer policies and clinical guidelines.

Frequently asked questions

How does Klivira handle step-therapy denials for asthma biologics?

Klivira's system is pre-configured with payer-specific step-therapy policies. Upon a denial for unmet step-therapy, it automatically identifies the required prior therapies, extracts documentation of their trial and failure from the EMR, and incorporates this evidence into the appeal letter to demonstrate medical necessity.

Can Klivira automate appeals for home oxygen or BiPAP equipment?

Yes, Klivira automates appeals for home oxygen, BiPAP, and CPAP equipment. The platform retrieves necessary documentation such as sleep study results, oxygen saturation levels, and physician orders from the EMR to support the medical necessity for these devices, drafting appeal letters that align with payer coverage criteria.

What clinical guidelines does Klivira reference for pulmonology appeals?

Klivira's platform incorporates logic informed by major pulmonology clinical guidelines, including GINA for asthma, GOLD for COPD, and ATS guidelines. This ensures that automated appeal letters and documentation requests align with accepted standards of care, bolstering the clinical argument for approval.

How does Klivira integrate with our EMR for pulmonology documentation?

Klivira integrates with your EMR using SMART on FHIR standards. This allows for secure, real-time access to patient data, including pulmonology-specific labs (e.g., eosinophil counts), imaging reports, physician notes, and medication histories, ensuring all relevant clinical evidence is automatically pulled for appeal submissions.

Does Klivira help with appeals for IPF antifibrotics?

Yes, for IPF antifibrotics like pirfenidone and nintedanib, Klivira assists by automating the retrieval of documentation related to diagnosis, disease progression, and prior conservative therapies. This evidence is then used to construct appeal letters that address payer requirements for these high-cost specialty medications.